Context Therapeutics Inc. (NASDAQ:CNTX – Free Report) – Stock analysts at HC Wainwright lowered their FY2024 earnings estimates for Context Therapeutics in a report issued on Wednesday, November 1st. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.84) for the year, down from their prior forecast of ($0.56). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Context Therapeutics’ FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.47) EPS and FY2027 earnings at ($0.36) EPS.
Context Therapeutics (NASDAQ:CNTX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.11).
Context Therapeutics Price Performance
CNTX opened at $1.25 on Friday. The company’s 50-day moving average is $1.13 and its 200 day moving average is $1.06. Context Therapeutics has a fifty-two week low of $0.47 and a fifty-two week high of $1.69. The firm has a market capitalization of $19.96 million, a P/E ratio of -1.07 and a beta of 2.51.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Two Sigma Investments LP raised its holdings in Context Therapeutics by 109.9% in the 1st quarter. Two Sigma Investments LP now owns 55,688 shares of the company’s stock worth $31,000 after purchasing an additional 29,154 shares during the period. State Street Corp boosted its holdings in Context Therapeutics by 79.8% in the third quarter. State Street Corp now owns 32,907 shares of the company’s stock valued at $37,000 after purchasing an additional 14,607 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Context Therapeutics during the 4th quarter worth about $38,000. Renaissance Technologies LLC raised its position in shares of Context Therapeutics by 47.4% during the 2nd quarter. Renaissance Technologies LLC now owns 28,300 shares of the company’s stock worth $45,000 after purchasing an additional 9,100 shares during the last quarter. Finally, Northern Trust Corp acquired a new stake in shares of Context Therapeutics during the 2nd quarter worth approximately $49,000. Institutional investors own 14.03% of the company’s stock.
About Context Therapeutics
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
- Five stocks we like better than Context Therapeutics
- What is ChatGPT Stock? How to Invest in It
- Shocking uranium play that hedge funds kept hidden
- What Does a Stock Split Mean?
- Dependable dividends: Why utility stocks are on fire
- Stock Dividend Cuts Happen Are You Ready?
- Realtor verdict, poor revenue guidance send Zillow stock plunging
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.